VISCHER Ltd advises the investors in a Series A round of CHF 18 million (EUR 9.5 million) led by Biomedinvest and BB Biotech Ventures in Aleva Neurotherapeutics SA in Lausanne. Aleva develops next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson's disease or depression. VISCHER led by Matthias Staehelin with Laura Rey advises the investors.